Children's National researcher authors study on pediatric brain stem tumors

December 03, 2013

Washington, DC-- Children's National researcher, Javad Nazarian, PhD, authored a new study entitled, "Comparative Multidimensional Molecular Analyses of Pediatric Diffuse Intrinsic Pontine Glioma Reveals Distinct Molecular Subtypes." The study found, for the first time, two distinct subtypes in pediatric diffuse intrinsic pontine gliomas (DIPG). It was published online in Acta Neuropathologica, a leading journal on pathology and pathogenesis of neurological disease.

This project was the first time researchers conducted a detailed analysis of proteome, transcriptome, methylome, and Histone H3 mutation profiles of DIPG specimens. One of the major results of the study was the discovery of two distinct subtypes of DIPGs and the identification of potential molecular pathways that lead to poorer overall survival of patients with histone 3 mutations.

DIPG is an aggressive tumor of the brain stem that cannot be surgically removed and is typically not biopsied due to the invasiveness of the procedure. For these reasons, a lack of tissue samples have contributed to a limited understanding of the tumor biology and hindered the development of treatments to improve survival rates.

"Pediatric DIPGs are almost always lethal, and most children do not survive beyond 18 months with this type of tumor," said Dr. Nazarian. "Our results have shown that a multidimensional molecular analysis can contribute to our understanding of DIPGs and guide future research for developing therapeutics."

Further study and a larger cohort of DIPG specimens are needed to identify all possible subtypes of DIPGs. Children's Research Institute (CRI) at Children's National Health System has generated the only published data on protein profiling of DIPGs. This is the third study on DIPG published by CRI.
-end-
Contact:

Emily Hartman or Caitlyn Camacho at 202-476-4500.

About Children's National Health System

Children's National Health System, based in Washington, DC, has been serving the nation's children since 1870. Children's National's hospital is Magnet® designated, and is consistently ranked among the top pediatric hospitals by U.S. News & World Report and the Leapfrog Group. Home to the Children's Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National is one of the nation's top NIH-funded pediatric institutions. With a community-based pediatric network, eight regional outpatient centers, an ambulatory surgery center, two emergency rooms, an acute care hospital, and collaborations throughout the region, Children's National is recognized for its expertise and innovation in pediatric care and as an advocate for all children. For more information, visit ChildrensNational.org, or follow us on Facebook and Twitter.

Children's National Health System

Related Tumor Articles from Brightsurf:

New cancer diagnostics: A glimpse into the tumor in 3D
A new technique could initiate a revolution in pathology: Tumor tissue is made transparent and illuminated with a special ultramicroscope.

Tumor progression depends on the tumor microenvironment
Researchers from Tokyo Medical and Dental University (TMDU) and Niigata University identified a novel mechanism by which tumors progress.

How do tumor cells divide in the crowd?
Scientists led by Dr. Elisabeth Fischer-Friedrich, group leader at the Excellence Cluster Physics of Life (PoL) and the Biotechnology Center TU Dresden (BIOTEC) studied how cancer cells are able to divide in a crowded tumor tissue and connected it to the hallmark of cancer progression and metastasis, the epithelial-mesenchymal transition (EMT).

Finding a way to STING tumor growth
The immune protein STING has long been noted for helping protect against viruses and tumors by signaling a well-known immune molecule.

Assembly within the tumor center
Number of macrophages in tumor tissue enables prognosis of lung tumor progression.

Mirror image tumor treatment
Our immune system ought to be able to recognize and kill tumor cells.

Traces of immortality in tumor DNA
To gain an infinite lifespan, cancer cells need to maintain the ends of their chromosomes, known as telomeres.

Peering into the genome of brain tumor
Scientists at Osaka University have created a machine learning method for classifying the mutations of glioma brain tumors based on MR images alone.

Glutamine-blocking drug slows tumor growth and strengthens anti-tumor response
A compound developed by Johns Hopkins researchers that blocks glutamine metabolism can slow tumor growth, alter the tumor microenvironment and promote the production of durable and highly active anti-tumor T cells.

Cancer genes and the tumor milieu
In a recent study published in Cancer Research, researchers demonstrate the role of an oncogene in altering the immediate environment of tumors.

Read More: Tumor News and Tumor Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.